世界卫生组织非典型性定义对手术治疗的功能性与无功能性垂体腺瘤的影响
回顾394例垂体腺瘤手术患者,29例(7.4%)符合WHO非典型性标准。功能性腺瘤缓解率47.4%,与非典型性无关;无功能性腺瘤中局部侵袭性与切除程度负相关(OR 0.255),非典型性与疾病进展/复发显著相关(OR 5.058)。作者认为非典型无功能性腺瘤有术后复发风险,但仅少部分肿瘤符合该定义,限制其临床实用性。
要点
- 394例中29例(7.4%)符合WHO非典型性标准。
- 功能性腺瘤缓解率47.4%,与非典型性无关。
- 无功能性腺瘤中非典型性与进展/复发相关(OR 5.058)。
核心结论
- 非典型无功能性垂体腺瘤患者存在术后复发和疾病进展风险,作者据此提出可能需要辅助治疗。
- 仅少部分垂体肿瘤符合WHO非典型性定义,限制了该定义的临床实用性。
研究设计与样本
- 回顾性分析接受垂体腺瘤手术患者的术前和术后记录,共纳入394例进行分析。
- 功能性腺瘤按当代缓解和复发定义评估术后结局;无功能性腺瘤根据术后磁共振成像定义切除范围和疾病进展。
主要发现
- 394例中29例(7.4%)符合非典型性标准。
- 非典型肿瘤患者显著年轻于典型腺瘤患者。
- 功能性腺瘤中47.4%可获得缓解,且与非典型性存在无关。
- 无功能性腺瘤中局部侵袭性与切除程度呈负相关(OR 0.255;95%CI 0.086-0.753;p<0.001)。
- 93例无功能性腺瘤术后平均37.5个月连续影像随访中,多因素分析显示疾病进展/复发与非典型性显著相关(OR 5.058;95%CI 1.273-20.098;p=0.021)。
关键数值与推荐
- WHO将非典型垂体腺瘤定义为MIB-1标记指数≥3%、p53阳性和核分裂活性增加。
- 功能性腺瘤缓解率47.4%。
- 无功能性腺瘤局部侵袭性与切除程度OR 0.255(95%CI 0.086-0.753;p<0.001)。
- 无功能性腺瘤疾病进展/复发与非典型性OR 5.058(95%CI 1.273-20.098;p=0.021)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 仅少部分垂体肿瘤符合WHO非典型性定义,限制了其临床实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization (WHO) defines atypical pituitary adenomas as tumours with a MIB-1 labelling index ≥3%, p53 positivity and increased mitotic activity. Although a few reports have described the clinical and radiological correlates of atypia in pituitary adenomas, its impact on postoperative outcomes is not clearly defined. METHOD: We reviewed preoperative and postoperative records of patients undergoing surgery for pituitary adenomas. Postoperative outcomes for functional adenomas (FPAs) were assessed according to contemporary definitions of remission and recurrence. For non-functional pituitary adenomas (NFPAs), extent of resection and disease progression were defined on the basis of postoperative magnetic resonance imaging. RESULTS: Of 394 patients included for analysis, 29 cases (7.4%) fulfilled criteria for atypia. Patients with atypical tumours were significantly younger than those with typical adenomas. Remission was possible in 47.4% of FPAs, and was unrelated to the presence of atypia. In NFPAs, local invasiveness was negatively associated with extent of resection (OR, 0.255; 95% CI, 0.086-0.753; p < 0.001). In 93 NFPAs followed postoperatively with serial imaging over a mean duration of 37.5 months, disease progression/recurrence was significantly associated with the presence of atypia (OR, 5.058; 95% CI, 1.273-20.098; p = 0.021) on multivariate analysis. CONCLUSIONS: Patients with atypical non-functional pituitary adenomas are at risk for postoperative recurrence and disease progression, suggesting a need for adjuvant therapy. However, only a small fraction of pituitary tumours demonstrate atypia, as defined by the WHO, limiting its clinical utility.
引用
- Sarkar S, Philip VJ, Cherukuri SK, et al. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas. Acta Neurochir (Wien). 2017. PMID: 28573325. doi:10.1007/s00701-017-3223-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。